XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Cash equivalents:    
Total cash equivalents $ 396,197 $ 362,008
Marketable securities:    
Investment in equity securities 49,803 43,653 [1]
Level 1    
Marketable securities:    
Investment in equity securities 40,000 35,500
Commercial Paper    
Cash equivalents:    
Total cash equivalents 20,967 159,758
Agency Discount Notes    
Cash equivalents:    
Total cash equivalents 323,086  
Recurring    
Cash equivalents:    
Total cash equivalents 396,197 362,008
Marketable securities:    
Total marketable securities 34,122 51,580
Investment in equity securities 49,803 43,653
LianBio Warrant 681 570
Total financial assets 480,803 457,811
Liability    
Embedded derivative 1,231 1,201
Short-term liability 5,490  
Total financial liabilities 6,721  
Recurring | Level 1    
Cash equivalents:    
Total cash equivalents 52,144 202,250
Marketable securities:    
Total marketable securities 0 0
Investment in equity securities 49,803 43,653
LianBio Warrant 681 570
Total financial assets 102,628 246,473
Liability    
Embedded derivative 0 0
Short-term liability 5,490  
Total financial liabilities 5,490  
Recurring | Level 2    
Cash equivalents:    
Total cash equivalents 344,053 159,758
Marketable securities:    
Total marketable securities 34,122 51,580
Investment in equity securities 0 0
LianBio Warrant 0 0
Total financial assets 378,175 211,338
Liability    
Embedded derivative 0 0
Short-term liability 0  
Total financial liabilities 0  
Recurring | Level 3    
Cash equivalents:    
Total cash equivalents 0 0
Marketable securities:    
Total marketable securities 0 0
Investment in equity securities 0 0
LianBio Warrant 0 0
Total financial assets 0 0
Liability    
Embedded derivative 1,231 1,201
Short-term liability 0  
Total financial liabilities 1,231  
Recurring | Money Market Funds    
Cash equivalents:    
Total cash equivalents 52,144 202,250
Recurring | Money Market Funds | Level 1    
Cash equivalents:    
Total cash equivalents 52,144 202,250
Recurring | Money Market Funds | Level 2    
Cash equivalents:    
Total cash equivalents 0 0
Recurring | Money Market Funds | Level 3    
Cash equivalents:    
Total cash equivalents 0 0
Recurring | Commercial Paper    
Cash equivalents:    
Total cash equivalents 20,967 159,758
Marketable securities:    
Total marketable securities 34,122 51,580
Recurring | Commercial Paper | Level 1    
Cash equivalents:    
Total cash equivalents 0 0
Marketable securities:    
Total marketable securities 0 0
Recurring | Commercial Paper | Level 2    
Cash equivalents:    
Total cash equivalents 20,967 159,758
Marketable securities:    
Total marketable securities 34,122 51,580
Recurring | Commercial Paper | Level 3    
Cash equivalents:    
Total cash equivalents 0 0
Marketable securities:    
Total marketable securities 0 $ 0
Recurring | Agency Discount Notes    
Cash equivalents:    
Total cash equivalents 323,086  
Recurring | Agency Discount Notes | Level 1    
Cash equivalents:    
Total cash equivalents 0  
Recurring | Agency Discount Notes | Level 2    
Cash equivalents:    
Total cash equivalents 323,086  
Recurring | Agency Discount Notes | Level 3    
Cash equivalents:    
Total cash equivalents $ 0  
[1] The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.